A Novel Miniature CRISPR-Cas13 System for SARS-CoV-2 Diagnostics

Area of Science:

• Molecular Biology
• Biotechnology
• Diagnostic Development

Background:

• Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics are laboratory-based, time-consuming, and unsuitable for rapid point-of-care (POC) use during epidemics.
• CRISPR-Cas systems offer sensitive and specific nucleic acid detection, leveraging RNA-guided enzymes and collateral cleavage activities.
• Expanding the diversity of CRISPR enzymes can enhance diagnostic capabilities.

Purpose of the Study:

• To identify and characterize novel CRISPR-Cas enzymes for improved diagnostic applications.
• To develop a rapid, sensitive, and specific POC diagnostic assay for SARS-CoV-2 detection.
• To evaluate the potential of new CRISPR systems for broader pathogen detection and future in vivo applications.

Main Methods:

• Identification and characterization of a new Cas13 variant, termed miniature Cas13 (mCas13).
• Development of a diagnostic module combining reverse transcription loop-mediated isothermal amplification (RT-LAMP) with the mCas13 system.
• Testing the system's performance using synthetic and clinical samples for SARS-CoV-2 detection.

Main Results:

• The novel mCas13 enzyme was successfully characterized for its catalytic activity.
• The integrated RT-LAMP and mCas13 system demonstrated high sensitivity and specificity for SARS-CoV-2 detection.
• Performance was comparable to existing CRISPR-based diagnostic systems.

Conclusions:

• The mCas13 system represents a valuable addition to the CRISPR toolbox for nucleic acid detection.
• This technology holds promise for rapid, scalable diagnostics of diverse pathogens, including viruses and bacteria.
• The findings support potential future applications in RNA knockdown, editing, and in vivo therapeutics.